Science

Generics and API Intelligence

THE GENERIC INDUSTRY OFFERS PHENOMENAL OPPORTUNITIES, AND A SUBSTANTIAL RISK

Built on more than a decade’s experience supplying solutions to meet critical business challenges in the highly competitive and global generic and API markets, Newport products are now used by more than 250 companies operating in 50 countries around the world.

HIGHLIGHTS

If you are a generic company, we can help you target products for development, locate qualified sources of API, monitor your competition, and find partners. Click to learn more

If you are an API manufacturer, we can help you target products for development, uncover buyers for your active ingredients, monitor your competition, and find partners. Click to learn more

If you are an innovator, we can help you monitor your competition, find licensing partners, and locate sources of API. Click to learn more

If you are specialty company, we can help you target products for development, locate qualified sources of API, monitor your competition, and find partners and licensing opportunities. Click to learn more

If you are a PBM, health insurer, or retail pharmacy, we can help you manage your costs by enabling you to identify likely suppliers and their relative negotiating strengths, intensity of competition, and timing of generic entry. Click to learn more

If you are a financial company, we can help you monitor generic competition for key products and companies. Click to learn more

Our solutions for Generics, API Manufacturers, PBMs, Pharmacies, and Analysts
  • Newport for Generics - Premium, Global, and Sourcing packages: The critical product targeting, global business development and API sourcing system from Thomson Reuters, the industry authority on the global generics market.
  • Newport Phase III Drugs Module - Intelligence on products still in phase III clinical trials or going through registrations.
  • Newport Generic Deals Module - Many thousands of merger, acquisition, development, supply, manufacturing, joint venture, patent settlement and authorized generic deals involving generic companies worldwide since 1999.
Our solutions for Innovators
  • Newport for Innovators - Premium, Global, and Sourcing packages: The most advanced competitive intelligence, business development and global active pharmaceutical ingredient (API) sourcing system from Thomson Reuters, the industry authority on the global generics market.
  • Newport Generic Deals Module - Many thousands of merger, acquisition, development, supply, manufacturing, joint venture, patent settlement and authorized generic deals involving generic companies worldwide since 1999.

 

 

DCAT WEEK

New York, New York, Waldorf Astoria
Tuesday, March 16 | 3:15pm - 4:45pm

How M&A Activity is Shaping the Future of the Industry and Your Business

David Harding, Newport Product Specialist, Thomson Reuters & Mike Chace-Ortiz, Sr. Director Product Strategy (API Intelligence), Thomson Reuters

In order to stay competitive in today’s market, many generic companies are relying on deals and collaborations to expand their portfolios and geographic reach, replenish or diversify their pipelines, secure access to active ingredients, as well as increase their manufacturing capacity and capabilities. This includes follow-on biologics, where few companies have the resources to develop and manufacture biologics on their own.

This session will provide in-depth data and market research on recent deal-making trends for generic companies, including details about which companies have been the most active over the past five years, the types of deals, how the deals have changed, and what will the future hold.

Member price: $59
Non Member price: $219
Website

PharmaSource 2010

Munich, Germany, Munich Marriott Hotel
Wednesday, March 24 | 9:55am

Mike Chace-Ortiz, Sr. Director, Product Strategy, API Intelligence, Thomson Reuters

Deal Making – The Life Blood of the Generic Industry – The Megatrends Part II

  • What are the key drivers for deal making in the generic industry?
  • Deal making as means to ensure access to active ingredients 
  • Pros and cons of backward integration
  • Deal making and generic biologics – what to expect?
Thursday, March 25 | 9:40am

Mike Chace-Ortiz, Sr. Director, Product Strategy, API Intelligence, Thomson Reuters

The ‘Emerging’ Emerging Markets – Where, When and at What Cost?

  • Key regional competencies for Pharma manufacturing and API supply outside of India and China
  • Comparing the expertise of suppliers and manufactures in Brazil, Russia, Vietnam, Indonesia, Bangladesh, and other markets
  • Deal making to take advantage of cost benefits in new markets
  • Lessons learned from sourcing from India and China
Thursday, March 25 | 11:30am

Successfully Sourcing from China – past experiences – who to select and who to avoid 

Mike Chace-Ortiz, Sr. Director, Product Strategy, API Intelligence, Thomson Reuters

Our overview of the most significant game-play in the US generics market.

Register 


 

Essential Solutions